Moomoo AI 已提取核心訊息
Kelly Schick, the Chief People Officer of C4 Therapeutics, Inc. (CCCC.US), has engaged in a transaction involving the company's stock on March 7, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares held by Schick after the action remains unknown.
Kelly Schick, the Chief People Officer of C4 Therapeutics, Inc. (CCCC.US), has engaged in a transaction involving the company's stock on March 7, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares held by Schick after the action remains unknown.
C4 Therapeutics, Inc.（CCC.US）的首席人事官凱利·希克於2024年3月7日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易的操作類型和狀態。因此，希克在行動後持有的股票數量仍然未知。
C4 Therapeutics, Inc.（CCC.US）的首席人事官凱利·希克於2024年3月7日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易的操作類型和狀態。因此，希克在行動後持有的股票數量仍然未知。
有用
沒用